Wednesday, May 23, 2012

Onyx crosses fingers as Bayer submits cancer drug to FDA

Onyx Pharmaceuticals Inc. will be paid royalties on sales of a Bayer drug aimed at colorectal cancer if it's approved by the Food and Drug Administration.
Bayer HealthCaresubmitted the drug, regorafenib, to the FDA seeking approval to use it to treat metastatic colorectal cancer. 

No comments:

Post a Comment